Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar 31;2(6):461-5.
doi: 10.1021/ml2000356. eCollection 2011 Jun 9.

Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors

Konrad Hohlfeld  1 , Cyrille Tomassi  1 , Jörg Kurt Wegner  2 , Bart Kesteleyn  2 , Bruno Linclau  1
Affiliations

Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors

Konrad Hohlfeld et al. ACS Med Chem Lett. .

Abstract

A series of darunavir analogues featuring a substituted bis-THF ring as P2 ligand have been synthesized and evaluated. High affinity protease inhibitors (PIs) with an interesting activity on wild-type HIV and a panel of multi-PI resistant HIV-1 mutants containing clinically observed, primary mutations were identified using a cell-based assay. A number of PIs have been synthesized that show equivalent and greater activity for HIV-1 mutant strains as compared to wild-type HIV-1. The activity on the purified enzyme was confirmed for a selection of analogues.

Keywords: HIV protease; bis-THF bis-diol; darunavir; inhibitors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure of DRV (1) and PIs 2−5.
Scheme 1
Scheme 1. Retrosynthetic Analysis of Inhibitors 3 and 5
Scheme 2
Scheme 2. Synthesis of Building Blocks 6b−j
Reagents and conditions: (a) NaH, DMF/THF; R-X, TBAI. (b) DMSO, Ac2O, AcOH. (c) (i) F−C6H4−NO2, KHMDS, THF; (ii) cyclohexene, Pd(OH)2, EtOH; (iii) tBuONO, BF3·OEt2, CH2Cl2; Cu powder, EtOH. (d) NaHMDS, THF; PMBCl, TBAI. (e) TBAF, THF. (f) DDQ, CH2Cl2/H2O. (g) H2, Pd/C, EtOH.
Scheme 3
Scheme 3. Synthesis of Inhibitors 1 and 2
Reagents and conditions: (a) Et3N, CH2Cl2. (b) Compound 7a or 7b, Et3N, CH2Cl2. (c) TBAF, THF (only for analogues b).
Figure 2
Figure 2
Three-dimensional depiction of possible binding modes of 3a (A) and 3h (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sepkowitz K. A. AIDS—The First 20 Years. N. Engl. J. Med. 2001, 344, 1764–1772. - PubMed
    1. Kohl N. E.; Emini E. A.; Schleif W. A.; Davis L. J.; Heimbach J. C.; Dixon R. A. F.; Scolnick E. M.; Sigal I. S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686–4690. - PMC - PubMed
    1. Johnson V. A.; Brun-Vezinet F.; Clotet B.; Gunthard H. F.; Kuritzkes D. R.; Pillay D.; Schapiro J. M.; Richman D. D. Update of the drug resistance mutations in HIV-1: December 2009. Top. HIV Med. 2009, 17, 138–145. - PubMed
    1. Ghosh A. K.; Thompson W. J.; Fitzgerald P. M.; Culberson J. C.; Axel M. G.; McKee S. P.; Huff J. R.; Anderson P. S. Structure-based design of HIV-1 protease inhibitors: Replacement of two amides an a 10π-aromatic system by a fused bis-tetrahydrofuran. J. Med. Chem. 1994, 37, 2506–2508. - PubMed
    1. Surleraux D. L. N. G.; Tahri A.; Verschueren W. G.; Pille G. M. E.; de Kock H. A.; Jonckers T. H. M.; Peeters A.; De Meyer S.; Azijn H.; Pauwels R.; de Bethune M.-P.; King N. M.; Prabu-Jeyabalan M.; Schiffer C. A.; Wigerinck P. B. T. P. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J. Med. Chem. 2005, 48, 1813–1822. - PubMed